{"id":671859,"date":"2026-03-21T16:24:20","date_gmt":"2026-03-21T16:24:20","guid":{"rendered":"https:\/\/www.europesays.com\/us\/671859\/"},"modified":"2026-03-21T16:24:20","modified_gmt":"2026-03-21T16:24:20","slug":"why-this-44-year-old-refuses-to-let-a-magic-weight-loss-drug-define-his-life","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/us\/671859\/","title":{"rendered":"Why This 44-Year-Old Refuses to Let a ‘Magic’ Weight Loss Drug Define His Life"},"content":{"rendered":"

Pranav Gupta may be 25 kg lighter today thanks to a weight loss drug he started on last June but he does not want to be dependent on it. Currently on a Mounjaro injectable,<\/a> he wants to get rid of it some day and doesn\u2019t want it to define his life. \u201cIt got me off a dangerous ledge called obesity, made me confident, made me do things that I should have done in my 20s. It made me self-correct and value myself and that\u2019s what I will choose once this drug does its job,\u201d says the 44 -year-old telecom distributor from Prayagraj, who had been living with morbid obesity over decades.<\/p>\n

Now, he is too self-aware to forget his exercise hour on the busiest of days, is fanatic about meal times and doesn\u2019t negotiate sleep for anything.<\/p>\n

\"\"<\/p>\n

At a time when obesity medicines are surrounded by hype and frenzy, Gupta remains grounded, watches his scale and makes sure to improve his lifestyle so that he doesn\u2019t need a drug when he does get down to 85 kg from his current 94 kg and can maintain himself thereon. \u201cI started out with the drug at 119 kg. And no matter what I did then, my body felt unwieldy and out-of-control. I needed help,\u201d he says.<\/p>\n

That\u2019s when he met Dr Subhash Wangnoo, head of the Apollo Centre for Obesity, Diabetes, and Endocrinology (ACODE), New Delhi<\/a>, who sees weight loss drugs as therapies within a larger medical frame. \u201cObesity is a chronic, relapsing, progressive disease. We now describe it as an adiposity-based chronic disease. It is driven by a combination of genetics, environmental factors and metabolism, rather than solely a lack of willpower. And it is disease-causing. The complications arise from unhealthy fat \u2014 particularly ectopic or out-of-place fat that lodges deep in the organs, particularly the abdomen. And that belly fat causes insulin resistance and inflammation, which unchecked leads to Type 2 diabetes<\/a> and heart disease,\u201d he says.<\/p>\n

For Indian patients, the \u201cthin fat\u201d syndrome complicates diagnosis. \u201cThis is a type of obesity where a person has high abdominal fat while having normal body weight. This heightens risks of cardiovascular and kidney disease, fatty liver, and epicardial fat deposition around the heart,\u201d Dr Wangnoo says. He prescribed Mounjaro, a once-weekly, injectable prescription medication approved for managing Type 2 diabetes, for Gupta. Its molecule tirzepatide functions by mimicking two hormones (GLP-1 and GIP) to regulate appetite and slow digestion, which results in significant weight loss as a side effect.<\/p>\n

\u201cCardiologists are increasingly prescribing tirzepatide for patients with Type 2 diabetes and high cardiovascular risk, as recent studies indicate it offers significant heart-protective benefits, including a reduction in major adverse cardiovascular events. Gupta was one such patient,\u201d says Dr Wangnoo.<\/p>\n

The beginning of obesity<\/p>\n

Gupta had been wrestling with diabetes, obesity and a family history since 2018. The diabetes drugs<\/a> didn\u2019t work well enough and he never thought that lifestyle changes could do much. The turning point was a severe road accident that left him paralysed for six months. He gained more weight during inactivity of the Covid years. \u201cThe road crash made me a quadriplegic. Though not permanently wheelchair-bound, my mobility was limited. I wanted the freedom to move around,\u201d says Gupta.<\/p>\n

Story continues below this ad<\/p>\n

By 2024, diabetes and inactivity had extracted a visible price. Cellulitis, a bacterial skin infection set in, leading to a seven-day hospitalisation with IV antibiotics. \u201cThat episode was a wake-up call,\u201d recalls Gupta. The blood sugar numbers were off the charts: fasting blood sugar was at 288 mg\/dL and HbA1c (average blood sugar count of three months) at 8.8. High-dose insulin shots had become routine.<\/p>\n

Not an easy journey with side effects<\/p>\n

Dr Wangnoo put Gupta on Mounjaro last June and escalated his doses gradually from 2.5 mg to 10 mg per week, one of the reasons he lost weight rapidly in 10 months. \u201cThe initial days were uneventful but later my sense of taste changed completely. Sweet, salt, sour, everything felt the same. I also had constipation and nausea,\u201d says Gupta. Metallic or bitter tastes are usually temporary side effects as the body adjusts. \u201cThis is because of reduced cravings, particularly for sweet or fatty foods, resulting from change in taste receptors and reduced reward signals in the brain,\u201d explains Dr Wangnoo.<\/p>\n

By September 2025, Gupta\u2019s fasting sugar had dropped to 102 mg\/dL and HbA1c to 5.4. Today, his fasting levels hover at 96 mg\/dL. Insulin is no longer part of the regimen. His sleep apnea, when breathing repeatedly stops and starts during sleep, and for which he needed the C-PAP machine to keep his airways open, has improved. \u201cThe side effects settled. What began were control and self-discipline,\u201d he says.<\/p>\n

Why lifestyle correction must go hand-in-hand<\/p>\n

One of the first advisories that Dr Wangnoo gives his patients is explain what the medication does. \u201cIt increases insulin release when blood sugar rises<\/a>, reduces sugar release from the liver, slows stomach emptying, so sugar enters the bloodstream slowly and reduces appetite that helps with weight loss,\u201d he says.<\/p>\n

Story continues below this ad<\/p>\n

He lays equal weightage on diet, exercise and sleep so that the gains made on medication can hold and are not frittered away. \u201cMost won\u2019t be able to continue the medication lifelong and giving up, as most trials show, means the weight returns and old risk factors resurface,\u201d says Dr Wangnoo.<\/p>\n

Gupta has a structured meal plan, has fibre and protein combinations with complex carbohydrates and keeps to his meal times. He also eats small portions throughout the day and drinks enough water in between. \u201cI finish breakfast by 8.30 am, usually poha with nuts, idli made with yogurt, dalia and almonds. It\u2019s fresh orange juice at noon. Lunch at 2 pm comprises vegetable salads and protein, a bowl of curd, dal or paneer. Brown rice or chapati some days. Late afternoon is about black coffee and a modest bhelpuri on days I do feel like eating. Dinner has been pared down to soup, two boiled eggs or a piece or two of boiled chicken. Earlier I could eat six to seven chapatis easily. No matter how late, if I didn\u2019t have wholesome dinner, I couldn\u2019t sleep. Now I often don\u2019t feel like eating meals. But spreading out has kept me energetic,\u201d Gupta has us know.<\/p>\n

His mobility improved in parallel. Guided physiotherapy \u2014 stretching, strength training, balance drills, chair exercises, knee extensions, hand and elbow work, even picking a ball off the floor \u2014 fills an hour daily. \u201cI couldn\u2019t walk or climb stairs. Now I can,\u201d Gupta says. The emotional arc is as significant. \u201cI came out of depression and looking at my body changes; am even determined to go for high-intensity routines.\u201d<\/p>\n

He can fall asleep on time. \u201cThe secret is letting your body digest before sleep and signing out of the phone. Now I manage seven to eight hours of sleep.\u201d Gupta is careful not to romanticise the injection. \u201cIt\u2019s the push, not the magic. Discipline does the heavy lifting.\u201d<\/p>\n

Story continues below this ad<\/p>\n

A word of caution<\/p>\n

Dr Wangnoo worries about the social media hype around weight loss drugs and generics flooding the market, now that patents have expired. \u201cThese are prescription drugs requiring supervision. Without medical oversight, who ensures pharmacovigilance?\u201d he asks.<\/p>\n

Screening is non-negotiable, he stresses, ruling out gallbladder disease, pancreatitis, significant alcohol use, thyroid disorders including cancer history and gastroparesis. Doses must be escalated gradually. Then there is affordability. \u201cIf stopped prematurely \u2014 say after a year or 18 months \u2014 weight often rebounds. Patients must be counselled,\u201d says Dr Wangnoo.<\/p>\n

Quality control remains a concern in a crowded marketplace. \u201cOriginal molecules undergo rigorous lab procedures. Real-world confidence comes after sustained prescribing experience,\u201d he adds. Notably, Indian patients often show strong responses, possibly linked to differences compared to Caucasian populations, says Dr Wangnoo.<\/p>\n

As for Gupta, his story is a reminder that while drugs can open the door, discipline should walk you through your weight loss journey. \u201cBuilding muscle mass is insurance. Consistency beats intensity. Pair exercise with protein while good sleep supports weight stability,\u201d advises Dr Wangnoo.<\/p>\n","protected":false},"excerpt":{"rendered":"Pranav Gupta may be 25 kg lighter today thanks to a weight loss drug he started on last…\n","protected":false},"author":3,"featured_media":671860,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[283533,283527,283528,210,1060,283531,283526,283529,283534,283530,13168,67,132,68,283532],"class_list":{"0":"post-671859","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-medication","8":"tag-adiposity-based-chronic-disease","9":"tag-dr-subhash-wangnoo-apollo","10":"tag-glp-1-gip-receptor-agonists","11":"tag-health","12":"tag-medication","13":"tag-mounjaro-vs-ozempic-for-diabetes","14":"tag-mounjaro-weight-loss-india","15":"tag-obesity-as-chronic-disease","16":"tag-pranav-gupta-weight-loss-journey","17":"tag-thin-fat-syndrome-india","18":"tag-tirzepatide-side-effects","19":"tag-united-states","20":"tag-unitedstates","21":"tag-us","22":"tag-weight-loss-drug-rebound"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@us\/116268097206714068","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/671859","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/comments?post=671859"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/671859\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media\/671860"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media?parent=671859"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/categories?post=671859"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/tags?post=671859"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}